Loading...
Market
What will be the stock price comparison of Eli Lilly and Novo Nordisk by end of 2024?
2
Resolution / Starting Odds
Eli Lilly > 20% increase • 25%
Eli Lilly 10-20% increase • 25%
Novo Nordisk 10-20% increase • 25%
Novo Nordisk > 20% increase • 25%
Official stock market data and financial news outlets
Story
JAMA Internal Medicine Study: Mounjaro Leads to Greater Weight Loss Than Ozempic
Jul 8, 2024, 04:00 PM
A new study published in JAMA Internal Medicine has found that Eli Lilly's Mounjaro (tirzepatide) leads to significantly greater weight loss compared to Novo Nordisk's Ozempic (semaglutide). The study, which involved 20,000 participants, used real-world data and matched propensity analysis to compare the effectiveness of the two drugs. Results indicate that patients taking Mounjaro lost more weight than those on Ozempic, and the longer the treatment duration, the wider the gap in weight loss between the two groups. Additionally, tirzepatide, the active ingredient in Mounjaro, also outperformed semaglutide in Wegovy and Zepbound.
View original story
Similar markets
Novo Nordisk outperforms • 25%
Eli Lilly outperforms • 25%
Both perform equally • 25%
Both underperform • 25%
Below $200 • 25%
$200 - $250 • 25%
$250 - $300 • 25%
Above $300 • 25%
Outperform significantly • 25%
Outperform slightly • 25%
Underperform • 25%
Match performance • 25%
VKTX outperforms both • 25%
VKTX outperforms NVO but not LLY • 25%
VKTX outperforms LLY but not NVO • 25%
VKTX underperforms both • 25%
Below $900 • 25%
$900 to $950 • 25%
$950 to $1000 • 25%
Above $1000 • 25%
Less than $400 • 25%
$400 to $450 • 25%
$450 to $500 • 25%
More than $500 • 25%
Less than $500 • 25%
$500 to $600 • 25%
$600 to $700 • 25%
More than $700 • 25%
